论文部分内容阅读
目的分析探讨硫普罗宁干预治疗对于急性白血病化疗患者因化疗所引起的白细胞减少以及肝功能损伤的临床治疗效果。方法本次研究选取了2009年9月~2012年8月期间本院收治的62例需要进行化疗的急性白血病患者作为研究对象,将全部患者随机分为对照组和研究组,每组患者各31例,其中研究组患者采用硫普罗宁进行干预治疗,对照组患者不进行干预治疗,对比两组患者的临床治疗效果。结果经过治疗,根据分度标准研究组患者的白细胞减少程度为21.8%、26.2%、35.1%和15.3%,对照组减少程度为13.4%、22.5%、35.2%和29.1%,组间差异明显(P<0.05)且差异具有统计学意义。结论利用硫普罗宁干预治疗急性白血病化疗引起的白细胞减少以及肝功能损伤能够达到理想的临床效果,值得推广。
Objective To investigate the clinical effect of intervention of tiopronin on chemotherapy-induced leukopenia and hepatic dysfunction in patients with acute leukemia chemotherapy. Methods A total of 62 patients with acute leukemia who underwent chemotherapy in our hospital from September 2009 to August 2012 were enrolled in this study. All patients were randomly divided into control group and study group, with 31 Cases, including the study group of patients with tiopronin intervention treatment, the control group of patients without intervention treatment, compared the clinical efficacy of two groups of patients. Results After treatment, the degree of leukopenia in the study group was 21.8%, 26.2%, 35.1% and 15.3%, and the reduction was 13.4%, 22.5%, 35.2% and 29.1% in the control group P <0.05) and the difference was statistically significant. Conclusion The use of tiopronin in the treatment of acute leukemia chemotherapy-induced leukopenia and liver damage can achieve the desired clinical effect, it is worth promoting.